Manmohan Singh, Ph.D. Vice President of Pharmaceutical Sciences and Delivery Technologies
Dr. Manmohan Singh is the Vice President of Pharmaceutical Sciences and Delivery Technologies at Beam Therapeutics. Dr. Singh has more than 24 years of drug discovery and development experience at Takeda Pharmaceuticals, Novartis and Chiron Corporation.
Prior to joining Beam Therapeutics, Dr. Singh was the Global Head of Drug Product Development at Takeda Vaccines, where he oversaw the drug product development of all vaccine programs, including Takeda’s dengue vaccine that was in Phase III efficacy study. At Novartis, he served as the Head of Formulation Development for more than 10 years and was instrumental in the licensure of several key vaccines (Bexsero , Fluad, Flucelvax) that were subsequently divested to GSK and CSL. He also led the development of the LNP platform of Novartis’s RNA vaccine. Prior to Novartis, Dr. Singh also spent more than 10 years at Chiron Corporation, where he led the development of Novel adjuvants and delivery systems for vaccines.
Based on his contributions at Chiron and Novartis, Dr. Singh is considered as one of the leading experts in the field of adjuvants and vaccine delivery systems. He has authored six books in this field and has more than 120 publications. He was elected as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2011.
Dr. Singh hold a Ph.D. in Pharmaceutics and Drug Delivery from the National Institute of Immunology in New Delhi, India.